Skip to main content

Table 1 Additional guidance for scoring the 10 PRECIS domains in the context of the BLISTER trial

From: The value of the pragmatic-explanatory continuum indicator summary wheel in an ongoing study: the bullous pemphigoid steroids and tetracyclines study

PRECIS domain

Description in the context of BLISTER

Eligibility criteria

Are most patients who would normally be treated included in the trial? How strict are the criteria?

Follow-up intensity

How similar to normal practice is the patient follow-up?

Primary outcomes

Would those considered to be a treatment success in the trial (for example, three or fewer blisters present at six weeks of follow-up) also be considered a treatment success in practice?

Method of analysing the primary endpoints

Are there many exclusions from the analysis? How inclusive is the definition of per-protocol?

Doxycycline and prednisolone flexibility

Can trial treatments be altered during follow-up or are patients expected to stay on the prescribed dose? Is this any different to normal practice?

Practitioner expertise on doxycycline and prednisolone

Are patients seen by specialists? Would they normally be seen by, for example, general practitioners?

Participant compliance

How closely is this measured? Are there interventions made to maintain or improve compliance?

Practitioner adherence to the protocol

Is the study concerned whether investigators ‘customise’ the trial to suit their own setting? Are all investigators expected to treat patients in the same way?